No new items were published in the sources we monitor on this date. The open consultations and hearings below remain current.
Federal Official Gazette
No updates.
ANS news
No updates.
Open public consultations
- CP 167. Subject: CP opened to collect criticism and suggestions regarding the preliminary recommendations contained in UAT No. 186 – Encorafenib, UAT No. 189 – Osimertinib and UAT No. 190 – Talazoparib. Deadline: Feb 10 to Mar 1.
Scheduled public hearings
There are no scheduled public hearings.
Open public calls for input
- The Public Call for Input (TPS) is hereby opened, intended for receiving suggestions on the priority supplementary health topics that will support the composition of the 2026-2028 Regulatory Agenda of the National Supplementary Health Agency (ANS). Extension: February 27, 2026.
Open public calls
No updates.
Other news
– No updates.
Sources: Federal Official Gazette (DOU) and the ANS website. Press items link to the original article. This brief is for information only and does not constitute legal advice.